Akero Therapeutics (FRA:0K4) 3-Year EBITDA Growth Rate : -3.50% (As of Jun. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Akero Therapeutics 3-Year EBITDA Growth Rate?

Akero Therapeutics's EBITDA per Share for the three months ended in Jun. 2024 was €-0.74.

During the past 3 years, the average EBITDA Per Share Growth Rate was -3.50% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was -23.20% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 7 years, the highest 3-Year average EBITDA Per Share Growth Rate of Akero Therapeutics was 2.00% per year. The lowest was -64.60% per year. And the median was -3.50% per year.

Competitive Comparison of Akero Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Akero Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akero Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akero Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Akero Therapeutics's 3-Year EBITDA Growth Rate falls into.

Akero Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Akero Therapeutics (FRA:0K4) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Akero Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Akero Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Akero Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akero Therapeutics Inc (FRA:0K4) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

AKRO:USA

Address

601 Gateway Boulevard, Suite 350, South San Francisco, CA, USA, 94080

Website

https://www.akerotx.com

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis, or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that has the potential to address the core processes underlying NASH pathogenesis.

Akero Therapeutics Headlines

No Headlines